La chaîne d'options affiche les données clés des options sur actions de Enanta Pharma à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Enanta Pharma..

Enanta Pharma (NASDAQ:ENTA) Stock, Chaîne d'Options

ENANTA PHARMACEUTICALS INC

Enanta Pharma

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharmaceuticals Inc

Entain PLC

Press Releases

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. "HCW@Home" Series

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

News

Biotech's Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM,  ENTA)

ARVN

ENTA

MDCX

RNTX

RYTM

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Cabaletta Bio

Caribou Biosciences

Cardiff Oncology

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Elicio Therapeutics

enGene Holdings

Eupraxia Pharmaceuticals Inc. - Common Stock

Eupraxia Pharmaceuticals

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Heron Therapeutics

TuHURA Biosciences

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Korro Bio

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Seres Therapeutics

MEI Pharma

Nkarta

Nuvectis Pharma

RAPT Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

Comments

Enanta Pharma

Enanta Pharma (ENTA) Options

Enanta Pharma (NASDAQ:ENTA) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL